Mouse a4b2 nicotinic acetylcholine receptors (nAchRs) were stably expressed in HEK293T cells. The function of this stable cell line, termed mma4b2, was assessed using an aequorinbased luminescence method that measures agonist-evoked changes in intracellular calcium. Agonist-elicited changes in intracellular calcium were due primarily to direct entry of calcium through the a4b2 channel, although release of calcium from intracellular stores contributed~28% of the agonistevoked response. Agonist pharmacologies were very similar between the mma4b2 cells and most cell lines that stably express human a4b2 nAchRs. Based on agonist profiles and sensitivity to the antagonist dihydro-b-erythroidine (DHbE), the predominant a4b2 nAchR expressed in the mma4b2 cells exhibits a pharmacology that most resembles the DHbE-sensitive component of 86 Rb + efflux from mouse brain synaptosomes. However, when evaluated with the aequorin assay, the mma4b2 nAchR was found to be atypically sensitive to blockade by the presumed a7-selective antagonist methyllycaconitine (MLA), exhibiting an IC 50 value of 31 ± 0.1 nM. Similar IC 50 values have been reported for the MLA inhibition of nicotine-stimulated dopamine release, a response that is mediated by b2-subunit-containing nAchRs and not a7-subunit-containing nAchRs. Consequently, at low nanomolar concentrations, MLA may not be as selective for a7-containing nAchRs as previously thought.
Alterations in intracellular calcium levels in neurons can affect a wide range of cellular processes including changes in gene expression, synaptic plasticity, neurotransmission and neurotransmitter release (for review, see Berridge 1998) . Changes in intracellular calcium levels in neurons and glia can arise from the entry of calcium via ligand-and voltagegated ion channels, as well as from the release of calcium from distinct intracellular stores. Neuronal nicotinic acetylcholine receptors (nAchRs), like ionotropic glutamate receptors, are ligand-gated ion channels that exhibit high permeability to calcium (Vernino et al. 1992; Bertrand et al. 1993; Seguela et al. 1993; Role and Berg 1996; Ragozzino et al. 1998) . Assembled from distinct combinations of subunits of the neuronal nAchR subunit family, numerous nAchR subtypes are expressed in the brain (Lindstrom 2003) . The neuronal nAchR subunit family includes nine a subunits, designated a2-a10 and three b subunits designated b2-b4. The nAchR subtype that exhibits the greatest calcium permeability relative to sodium is the a7 homomeric nAchR (Bertrand et al. 1993; Seguela et al. 1993; Castro and Albuquerque 1995) . Another nAchR subtype that is calcium permeable is the subtype composed of a4 and b2 subunits (Vernino et al. 1992; Ragozzino et al. 1998) .
The a4b2 nAchR is the most abundant nAchR subtype expressed in the brain, and studies have demonstrated that this receptor subtype is located presynaptically on GABAergic (Alkondon et al. 1996; Lu et al. 1998; Zhu and Chiappinelli 1999; Klink et al. 2001 ) and dopaminergic terminals (Grady et al. 1992; Klink et al. 2001; Champtiaux et al. 2002; Zoli et al. 2002) . This nAchR subtype is elevated in brain tissue from smokers (Benwell et al. 1988; Breese et al. 1997) and reduced in brain tissue from Alzheimer's disease patients (Flynn and Mash 1986; Nordberg and Winblad 1986; Whitehouse et al. 1986 ). Rare alleles for the genes that encode the a4 and b2 subunits have been identified in humans and are associated with autosomaldominant nocturnal frontal lobe epilepsy (Steinlein 2004 for review) .
Like humans, mice chronically exposed to nicotine exhibit an increase in a4b2 nAchRs in brain (Marks et al. 1983 ). In addition, mice engineered to lack this nAchR subtype exhibit learning deficits (Picciotto et al. 1995) , loss of the neuroprotective effect of nicotine on 6-OH DOPA lesions in the striatum (Ryan et al. 2001) and do not show reinforcement by nicotine (Epping-Jordan et al. 1999 ). Studies have also described a polymorphism in the mouse a4 subunit gene that is associated with functional differences in a4b2 nAchRs in mouse brain synaptosomes (Stitzel et al. 2001; Dobelis et al. 2002) and affects receptor function in a heterologous expression system (Kim et al. 2003) . This polymorphism is associated with mouse strain differences in sensitivity to nicotine-induced seizures (Stitzel et al. 2000) and other responses to nicotine (Tritto et al. 2002; Butt et al. submitted) , as well as individual differences in responsiveness to alcohol (Owens et al. 2003; Butt et al. 2004) .
Owing to the heterogeneity of nAchRs in the brain, it is difficult to evaluate the pharmacology and cell biology of individual native nAchR subtypes. This complication limits the ability to assess how variations in receptor function of specific nAchR subtypes might contribute to such processes as addiction and disease. In an attempt to establish the pharmacology and cell biology of individual nAchR subtypes, several heterologous expression systems that stably express specific nAchR subtypes, including the a4b2 nAchR subtype Chavez-Noriega et al. 2000; Michelmore et al. 2002; Eaton et al. 2003; Nelson et al. 2003) have been developed. However, despite the increasing number of these nAchRexpressing cell lines, an extensive comparison of the pharmacology of receptor function between these cell lines and native a4b2 nAchRs has not been reported. In the data described here, HEK293T cells that exhibit stable expression of a functional mouse a4b2 nAchR are described. Agonist-evoked increases in intracellular calcium by eight agonists and inhibition of the agonistevoked response by five antagonists were assessed in this cell line. In addition, the mechanism of agonist-induced changes in intracellular calcium in this cell line was evaluated. Finally, in order to evaluate the similarity between heterologously expressed mouse a4b2 nAchRs and native mouse a4b2 nAchRs, the agonist and antagonist profiles of the mouse a4b2 cell line were compared with the pharmacological profiles of native a4b2 nAchRmediated 86 
Rb
+ efflux from mouse brain thalamic synaptosomes.
Materials and methods
Cell culture HEK293T cells were maintained at 37°C in a humidified, 5% CO 2 environment in Dulbecco's modified Eagle's medium (high glucose, no pyruvate) (DMEM), 10% heat-inactivated fetal bovine serum and antibiotic/antimycotic (100 U/mL penicillin, 100 lg/mL streptomycin and 0.25 lg/mL amphotericin B). Culture reagents were purchased from either Biowhittaker (East Rutherford, NJ, USA) or Invitrogen (Carlsbad, CA, USA).
Generation of a HEK293T cell line stably transfected with mouse a4 and b2 nAchR subunits Mouse nAchR a4 and b2 subunit cDNAs were introduced into the mammalian expression vectors pcDNA3.1zeo (Invitrogen) and pcDNA3.1hygro (Invitrogen), respectively, as previously described (Kim et al. 2003) . For transfection, HEK293T cells were plated at a density of 5 · 10 6 cells/100 mm dish in DMEM supplemented with 10% fetal bovine serum and antibiotic/antimycotic. The day following plating, the cells were transfected with the mouse a4 and b2 cDNA constructs using LipoFectamine Plus Reagent (Invitrogen) according to the manufacturer's suggested protocol. The A529 variant of the mouse a4 cDNA (Kim et al. 2003) was used for the transfection. Approximately 48 h following transfection, the media was supplemented with 0.05 mg/mL zeocin (Invitrogen) and 0.25 mg/mL hygromycin sulfate in order to select for cells that had stably integrated the a4 and b2 expression vectors, respectively. Following 1 week of selection with zeocin and hygromycin, the concentrations of these drugs were increased to 0.1 and 0.5 mg/mL, respectively. The cells then were maintained under these conditions for 2-3 additional weeks. After this drug selection period, the cells were trypsinized and transferred to a new culture vessel. The cells always were maintained under selection with 0.1 mg/mL zeocin and 0.5 mg/mL hygromycin.
Isolation of stable transfectants enriched for surface nAchR expression Pooled, stably transfected cells were removed from a near confluent 75 cm 2 flask by gentle aspiration with phosphate-buffered saline (PBS) and transferred to a 5 mL sterile polypropylene tube. Following centrifugation at 4°C for 5 min at 800 g, the PBS was removed and the cells were resuspended at a density of 5 · 10 6 cells/mL in PBS supplemented with 2% heat-inactivated fetal bovine serum and 0.05% sodium azide (flow buffer). The antia4-specific monoclonal antibody mAb299 (Covance, Berkeley, CA, USA) (Whiting and Lindstrom 1988 ) was added to the cells at a 1/500 dilution and the cells were incubated for 1 h at 4°C with gentle rocking. After incubation with mAb299, the cells were centrifuged as described above, rinsed with flow buffer, and centrifuged once again as described above. The wash and centrifugation steps were repeated a total of three times. After the third wash, the cells were resuspended in flow buffer and a biotin-conjugated rabbit antirat polyclonal antibody (Zymed Laboratories, South San Francisco, CA, USA) was added to the cell suspension at a 1/500 dilution. The cells then were incubated at 4°C for 30 min with gentle rocking and subsequently washed exactly as described above. Upon completion of the wash steps, the cells were resuspended in flow buffer, streptavidin-conjugated phycoerythrin was added to the cell suspension at a 1/200 dilution, and the cells were incubated at 4°C in the dark for 20 min with gentle rocking. Following this incubation, cells were centrifuged as described above, resuspended in PBS + 0.05% sodium azide and recentrifuged. Resuspension of the cells and centrifugation was repeated a total of three times. After the final wash and centrifugation step, the cells were resuspended at a density of 5 · 10 6 cells/mL in PBS + 0.05% sodium azide. Propidium iodide was added to the cells at a final concentration of 2.5 lg/mL and following 5 min incubation, the cells were transported to the University of Michigan Flow Cytometry Core. Viable cells that were surface-positive for mAb299 were sterile sorted by the Flow Cytometry Core. To identify viable, mAb299 surface-positive cells, the stable transfectants were compared against non-transfected HEK293T cells that had been mAb299 stained side-by-side with the stable line. Approximately 37% of the cells analyzed were identified as viable, mAb299-positive cells. The mAb299-positive cells were seeded in a culture flask in DMEM, 10% fetal bovine serum, antibiotic/antimycotic solution and selection drugs as described above and allowed to propagate to near confluence. Subsequent passages (passages 1-10) of these cells were used for all experiments in this report. These cells were designated as mma4b2 (Mus musculus a4b2). Approximately 72 h after plating, the cells were scraped from the dishes and membrane fractions were prepared as previously described , with the exception that a 15 min incubation at 37°C with 50 lg/mL DNAse was performed prior to the first centrifugation. H]-epibatidine. Non-specific binding was determined by the inclusion of 10 lM nicotine in the reaction. The binding reaction was terminated by filtration of the protein onto glass fiber filters that had been treated with 0.5% polyethylenimine in KRH buffer. Filtration was performed using a Tomtec Mach II cell harvester (Tomtec, Hamden, CT, USA). After filtration, the filters were washed four times with ice-cold buffer. The filters were collected and placed in scintillation vials. Following the addition of 3 mL scintillation fluid, the radioactivity was measured using a liquid scintillation counter (Beckman Coulter, Fullerton, CA, USA (Lowry et al. 1951) .
Electrophysiological recording from mma4b2 cells mma4b2 cells were maintained in a humidified 5% CO 2 environment at 37°C in DMEM supplemented with 10% fetal bovine serum and antibiotics (100 U/mL penicillin, 100 lg/mL streptomycin). Between 24 and 48 h prior to recording, the cells were plated at a density of 3 · 10 5 cells/60 mm dish and maintained in a humidified 5% CO 2 environment at 30°C. For whole-cell recording, the external solution consisted of 140 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 2 mM CaCl 2 , 10 mM glucose, 10 mM HEPES, pH 7.3. Recording electrodes were filled with an internal solution of 140 mM CsCl, 4 mM NaCl, 4 mM MgCl 2 , 0.5 mM CaCl 2 , 5 mM EGTA, 10 mM HEPES pH 7.3, with 4 mM ATP added on the day of recording. nAchR receptor currents were recorded using a lifted whole-cell patch-clamp technique. Agonist was applied to cells using a modified SF-77B Perfusion Fast-Step application system (Warner Instrument Corp., Hamden, CT, USA). The application system provided for simultaneous flow of all solutions to which the cells were exposed through three parallel glass square barrels. All step protocols began with a cell positioned in the flow of external bath solution from which the multibarrelled array was repositioned such that the unmoved cell and electrode were now exposed to acetylcholine (Ach). All cells were voltage clamped at )50 mV during recordings. Currents were recorded using a 200B amplifier (Axon Instruments, Union City, CA, USA). All experiments were performed at room temperature (22°C). Whole cell currents were analyzed using the programs PCLAMP 9.0 and PRISM (GraphPad, San Diego, CA). Whole-cell current amplitudes were obtained by measuring the peak current evoked during the application of drug. For Ach and tetramethylammonium chloride (TMA) concentrationresponse curves, the data were normalized to a percent of the maximum current elicited by saturating agonist concentrations for each cell. For methyllycaconitine (MLA) inhibition curves, MLA was applied to the cells for 1 s prior to the application of a solution containing 10 lM nicotine and the pre-application concentration of MLA. Normalized concentrationresponse data were curve fitted using the sum of two Michaelis-Menten equations.
Aequorin intracellular calcium measurement assay
Cell preparation mma4b2 cells were seeded onto six-well plates (1 · 10 6 cells/well) or 100 mm dishes (5 · 10 6 cells/dish) and the following day transfected with the plasmid pcDNA into which a human codonoptimized aequorin cDNA had been cloned (Vernon and Printen 2002) . Transfection was performed using the LipofectAmine Plus Reagent as recommended by the manufacturer (Invitrogen). Approximately 48-72 h following transfection, culture media was replaced with DMEM + 0.1% fetal bovine serum and 2.5 lM coelenterizine-hcp (Molecular Probes, Eugene, OR, USA) and the cells were incubated for 3-4 h at 37°C in a humidified 5% CO 2 incubator. Following the coelenterizine incubation, cells were gently aspirated from the culture dishes and transferred to either 2 mL (sixwell plates) or 15 mL (100 mm dishes) centrifuge tubes. An equal volume of Hank's balanced salt solution supplemented with 100 mM calcium chloride was added and the cells were incubated for 5-10 min at room temperature. This step eliminated an artifactual injection peak presumably resulting from entry of calcium into non-viable permeable cells. The cells were then pelleted by centrifugation at 4°C for 5 min at 800 g, the supernatant was discarded, and the cells were resuspended in 1· assay buffer (130 mM NaCl, 5.4 mM KCl, 10 mM CaCl 2 , 5 mM glucose, 25 mM HEPES, pH 7.5) and again pelleted by centrifugation. Subsequently, the cells were resuspended in fresh 1· assay buffer (1 mL/well of a six-well plate or 6 mL/100 mm dish) and incubated for 1-2 h at 4°C prior to initiating the assay.
Aequorin assay
For agonist concentration-response curves, 50 lL of each agonist concentration (in assay buffer) was added to each well of a 96-well opaque plate which was placed in a Beckman-Coulter LD400 luminometer. mma4b2 cells were placed in a 7 mL scintillation vial connected to a luminometer injector line and gently mixed continuously with a stir bar. For Ach stimulations, the cells were incubated with 1 lM atropine for 10-15 min at room temperature prior to initiating the assay. The assay was initiated by injection of 50 lL of cells into each well of the agonist-containing plate. Agonist-stimulated luminescence was recorded at 0.15-0.2 s intervals for 15-20 s immediately following the addition of cells to each well. Each agonist concentration was measured in duplicate per aequorin transfection. Once the concentration-response recordings were complete for an entire 96-well plate, remaining aequorin luminescence was determined by injecting 100 lL of a solution containing 0.1% Triton X-100 and 100 mM CaCl 2 into each well and recording luminescence for 5 s at 0.1 s intervals. In order to control for differences in cell number per well and variation in the transfection efficiency of aequorin, agonist-stimulated luminescence was normalized by dividing the maximal peak value for the agoniststimulated luminescence (L) by the total peak luminescence value (L max ) (maximal peak agonist-stimulated luminescence + maximal peak luminescence resulting from cell lysis in the presence of high calcium). All data, except raw data traces, are presented as the percent of total possible calcium-stimulated luminescence (L/L max ). For antagonist concentration response curves, 25 lL of mma4b2 cells was added to each well of an opaque 96-well plate along with 25 lL of the appropriate antagonist. The cells and antagonists were mixed and incubated for 10 min at room temperature. Following the 10 min incubation, 50 lL of 10 lM nicotine was injected onto the cells and luminescence was recorded at 0.2 s intervals for 20 s. Marks et al. (1999) used a concentration of 10 lM nicotine to evaluate antagonists IC 50 values for a 'dihydro-b-ethroidine sensitive' a4b2 nAchR subtype present in mouse brain synaptosomes. Therefore, 10 lM nicotine was used for the antagonist experiments with the mma4b2 cells so that a comparison of the IC 50 values could be made between the mma4b2cells and 'dihydro-b-ethroidine sensitive' a4b2nAchRs present in mouse brain synaptosomes. After agonist incubation, total luminescence per well was recorded by injection of 100 lL of 0.1% Triton X-100 and 100 mM CaCl 2 and recording luminescence for 5 s at 0.1 s intervals. All data are presented as L/L max as described above.
Experiments with the voltage-sensitive calcium channel inhibitor CdCl 2 (100 lM), and the inhibitors of intracellular calcium release, ryanodine (30 lM) and xestospongin C (10 lM), were performed exactly as described for the antagonist experiments with the exceptions that the cells were incubated with the compounds for 30 min prior to agonist application and 1 lM epibatidine was used as the agonist rather than 10 lM nicotine. The concentration used for each inhibitor was based on data from others (Gafni et al. 1997; Gueorguiev et al. 2000; Sharma and Vijayaraghavan 2001; Shoop et al. 2001; Dajas-Bailador et al. 2002) .
Data analysis
Whole cell recording data were fitted to a two-site model using the sum of two Michaelis-Menten equations. Concentration-response curves for the aequorin assay were fitted to a four parameter logistic equation using PRISM 3.0 software. All data are represented as mean ± S.E.M.
Results
Generation of a cell line that expresses mouse a4b2 nicotinic receptors Plasmids carrying the cDNAs for the mouse nAchR subunits a4 and b2 were transfected into HEK293T cells as described above. Following several weeks of growth in media supplemented with zeocin and hygromycin to select for cells that had stably integrated both plasmids, the cells were pooled and viable cells that were surface positive for the a4 subunit were immuno-isolated with the a4 subunit-specific antibody mAb299 (Whiting and Lindstrom 1988) by fluorescenceactivated cell sorting. Approximately 37% of the viable cells were selected as mAb299 immunopositive. These immunopositive cells, hereafter referred to as mma4b2, were propagated for experimental procedures. All experiments described in this report utilized the mma4b2 cells between generations 2 and 10.
Ligand binding of mma4b2 cells
To verify the expression of a4b2 nAchRs in the mma4b2 cells, saturation binding with [ 3 H]-epibatidine was performed (Fig. 1) Figure 2 shows the concentration-response of the mma4b2 cells to Ach. Curve fitting indicated that the Ach response curve was consistent with a two-component response with the lowaffinity response exhibiting an EC 50 of 179 ± 22 lM, and the high-affinity component possessing an EC 50 value of 3.36 ± 2.25 lM. The low-affinity component was responsible for~90% of the total response. The high proportion of the low-affinity response relative to the high-affinity response is consistent with other reports on the stable expression of a4b2 nAchRs in HEK cells (Buisson and Bertrand 2001; Nelson et al. 2003) .
Agonist-stimulated increase in intracellular calcium: requirement for extracellular calcium In order to further characterize the function of the mma4b2 cell line, agonist-stimulated changes in intracellular calcium were determined using an aequorin-based luminescence assay (Brini et al. 1995; Vernon and Printen 2002) . Several studies have demonstrated that the measurement of nicotinic receptor-mediated changes in intracellular calcium is dependent upon the concentration of extracellular calcium (Ragozzino et al. 1998; Xiao et al. 1998; Chavez-Noriega et al. 2000; Pacheco et al. 2001; Michelmore et al. 2002) . Therefore, the extracellular calcium requirement for nicotinic agonist-stimulated changes in intracellular calcium in the mma4b2 cell line was addressed by stimulating aequorintransfected mma4b2 cells with 1 lM epibatidine in the presence of concentrations of extracellular calcium ranging from nominally 0 to 10 mM. Figure 3 shows the raw data traces of 1 lM epibatidine-stimulated luminescence over a 15 s recording period. Consistent with previous reports, increasing the concentration of extracellular calcium resulted in an increase in the response to the 1 lM epibatidine stimulation. Consequently, all experiments described below were performed in the presence of 10 mM calcium, the highest concentration of extracellular calcium tested.
Pharmacological characterization of agonist-induced increases in intracellular calcium in mma4b2 cells Eight nAchR agonists were tested for their potency and efficacy in stimulating an increase in intracellular calcium concentrations. Figure 4(a) shows the raw data traces of aequorin luminescence following stimulation with epibatidine concentrations ranging from 30 nM to 0.3 lM. As the epibatidine concentration was increased, the luminescence peak increased and became more distinct. The time to peak luminescence also decreased as the concentration of agonist increased. This concentration-dependent temporal shift in the aequorin peak response is a common feature of the aequorin-based assay. For example, Ungrin et al. The concentration-response relationship was obtained by normalizing the peak response for each concentration of Ach to the maximal current response for each cell. (a) Data points for the concentration-response curve represent the mean ± SEM of between four and eight separate measurements per Ach concentration. Data were fitted using the sum of two Michaelis-Menten equations. EC 50 values for the low-(EC 50L ) and high-affinity (EC 50H ) components of the Ach response curve were estimated to be 179 ± 22 and 3.36 ± 2.25 lM, respectively. Peak current for the low-(I maxL ) and high-affinity (I maxH ) components were estimated to be 1.05 ± 0.03 and 0.11 ± 0.035, respectively.
(1999) described this temporal shift in response to increasing concentrations of prostanoids. Concentration-response curves for epibatidine, as well as Ach, A85380, cytisine, dimethylphenylpiperazinium iodide (DMPP), methylcarbachol, nicotine and TMA are shown in Fig. 4(b) . Because electrophysiological data indicated that 90% of the Ach response was due to a single component, data were fitted assuming single population kinetics. Of the agonists tested, epibatidine exhibited the lowest EC 50 value (0.033 ± 0.001 lM) and Ach the highest (66.3 ± 2.23 lM) ( Table 1 ). The rank order of EC 50 values for the a4b2-mediated increase in intracellular calcium levels was epibatidine < A85380 < DMPP ¼ nicotine < MCC < TMA < Ach. An EC 50 value was not calculated for cytisine because the response to this drug did not fit a sigmoidal concentration-response curve. Of the agonists tested, Ach was the most efficacious in stimulating an increase in intracellular calcium, whereas cytisine was the least efficacious. The rank order of efficacy of the agonists was Ach > epibatidine ¼ MCC ¼ TMA > A85380 > nicotine > DMPP > cytisine (Table 1) .
Antagonist inhibition of nicotine-stimulated intracellular calcium in mma4b2 cells
The ability of the nAchR antagonists decamethonium (DEC), dihydro-b-erythroidine (DHbE), hexamethonium (HEX), mecamylamine (MEC) and MLA to inhibit the increase in intracellular calcium in response to 10 lM nicotine was assessed in the mma4b2 cells. Raw data traces of the effect of increasing concentrations of DHbE on the nicotine-stimulated increase in intracellular calcium Table 1 .
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are shown in Fig. 5(a) . Full concentration-response curves for the five antagonists are provided in Fig. 5(b) . MLA was the most potent antagonist at inhibiting the nicotinestimulated increase in intracellular calcium (IC 50 ¼ 31.6 ± 1.2 nM), whereas HEX and DEC were the least potent (1.96 ± 0.13 and 2.52 ± 0.21 lM, respectively). The rank order of antagonist IC 50 values was MLA < DHbE ¼ MEC < HEX ¼DEC (Table 2) .
Mechanism of nicotine-stimulated increase in intracellular calcium
Changes in intracellular calcium following nAchR stimulation can result from direct entry of calcium through the a4b2 nAchR, as a result of activation of voltage-sensitive calcium channels or as a consequence of the release of intracellular stores of calcium. To identify the mechanism through which a4b2 nAchR stimulation increases intracellular calcium, cells Table 2 . Values for the mma4 b2 cells were calcuted by non-linear least squares curve fitting of the data shown in Fig. 4 were stimulated with 1 lM epibatidine in the presence of either 100 lM CdCl 2 , 30 lM ryanodine or 10 lM xestospongin C as described above (Fig. 6) . Inclusion of the general high-voltage sensitive calcium channel inhibitor CdCl 2 had no effect on the levels of epibatidine-stimulated intracellular calcium. In contrast, inhibition of ryanodine receptordependent intracellular calcium release by ryanodine or IP3-receptor-dependent intracellular calcium release by xestospongin C reduced epibatidine-stimulated intracellular calcium to 80 ± 1.3 and 85.4 ± 3.0% of control, respectively. Inclusion of both ryanodine and xestospongin C led to a response that was 72.1 ± 4.6% of the control response. Therefore, the nicotinic agonist-stimulated changes in intracellular calcium as measured with the aequorin-based assay appear to be predominantly due to entry of calcium through the receptor channel with a contribution of~28% from the release of calcium from intracellular stores.
Discussion
We report the functional characterization of a cell line that stably expresses a mouse a4b2 nAchR. This is the first report of a stable heterologous expression system for the characterization of mouse a4b2 nAchRs. Moreover, this is the first report where the aequorin-based luminescence assay was used to measure neuronal nAchR-mediated changes in intracellular calcium. The aequorin assay provides a new and relatively simple method to measure nAchR function in mammalian cell culture systems. Consistent with previous reports (Buisson and Bertrand 2001; Nelson et al. 2003) , stable expression of mouse a4b2 nAchRs in HEK293T cells leads to the expression of two receptor populations. The predominant subpopulation (90% of the whole-cell patch-clamp response) of receptors exhibits an EC 50 value for Ach of 179 ± 22 lM and the minor component has an EC 50 value for Ach of 3.36 ± 2.25 lM. Using HEK cells stably transfected with the human a4 and b2 nAchR subunits, Nelson et al. (2003) recently demonstrated that the receptor population with high Ach affinity (EC 50 ¼ 0.7 ± 0.4 lM) has a stoichiometry of a4 2 b2 3 and the low-affinity population (EC 50 ¼ 74 ± 6 lM) represents a4b2 nAchRs with a stoichiometry of a4 3 b2 2 . Therefore, the low Ach sensitivity of the predominant a4b2 nAchR in the mma4b2 cells is consistent with an a4b2 nAchR that has a stoichiometry of a4 3 b2 2 .
Comparison of the aequorin assay-determined EC 50 values for the mma4b2 line with those of human a4b2 nAchRs stably expressed in HEK cells indicates that the pharmacology of the mouse and human a4b2 nAchR are very similar (Table 1) . The correlation between the EC 50 values for the mouse and human a4b2 cell lines for the four common agonists tested between studies (Ach, epibatidine, DMPP and nicotine) is 0.984 (r, p < 0.01, slope ¼ 1.02) when compared with human a4b2-mediated changes in intracellular calcium (Chavez-Noriega et al. 2000) and 0.973 (r, p < 0.05, slope ¼ 1.00) when compared with human a4b2-mediated 86 Rb + efflux . Also, the mma4b2 cell line exhibited an EC 50 value for Ach activation (66.3 ± 2.28 lM) that is quite similar to the EC 50 value for Ach observed in a variety of independently derived human a4b2 HEK stable cell lines (43.79 ± 1.18 lM, Gopalakrishnan et al. 1996; 100 lM, Chavez-Noriega et al. 2000; 74 ± 6 lM, Nelson et al. 2003) and to the EC 50 value for Ach in oocytes when equal amounts of a4 and b2 cRNAs are injected (65.6 ± 20.2, Zwart and Vijverberg 1998) .
When the pharmacology of the mma4b2 cell line was compared with that of human a4b2 cells stably expressed in SH-EP cells (Eaton et al. 2003) , no significant correlation Fig. 6 Role of voltage-operated calcium channels and intracellular calcium stores in the epibatidine-evoked increase in intracellular calcium in mma4b2 cells. Aequorin/coelenterizine-hcp-loaded mma4b2 cells were stimulated with 1 lM epibatidine after 30 min incubation with vehicle (control), 100 lM CdCl 2 , 30 lM ryanodine (Ry) and 10 lM xestospongin C (XeC) or 30 lM ryanodine + 10 lM xestospongin C (Ry + XeC). Immediately upon injection of epibatidine onto the cells, luminescence was recorded at 0.2 s intervals for 20 s. Data were calculated as the ratio of agonist-induced peak aequorin luminescence (L) divided by the sum of the possible aequorin luminescence (L max ; peak agonist induced luminescence + peak luminescence following cell lysis in the presence of 50 mM calcium). Results presented represent the percent L/L max relative to the epibatidine response in the presence of vehicle. Data shown represent the mean ± SEM of between three and six independent aequorin transfections per drug treatment). Data were analyzed by means of one-way ANOVA. **p < 0.001 relative to control response. IC 50 values were calculated using by non-linear least squares curve fitting of the curves shown in Fig. 5 . Values given are mean ± SEM. Mean values were calculated from a minimum of four separate aequorin transfections.
Function of mouse a4b2 nicotinic receptors 1145 was detected (adjusted R 2 ¼ ) 0.18, p > 0.5). This lack of correlation is driven by the~35-fold lower EC 50 values for Ach and epibatidine in the SH-EP cells. The observation that a4b2 nAchRs in SH-EP cells exhibit an EC 50 value for Ach in the 1 lM range suggests that the receptor stoichiometry in this cell line may be (a4) 2 (b2) 3 (Zwart and Vijverberg 1998; Nelson et al. 2003; Zhou et al. 2003) . However, there are other possible explanations for the differences in pharmacology of the a4b2 nAchRs expressed in the SH-EP cells relative to the HEK cells such as cell-type differences in lipid composition (Zanello et al. 1996) or cell-type specific receptor-protein interactions (Lin et al. 2002) .
A 86 Rb + efflux assay has been utilized to demonstrate that there are two major pharmacologically distinct responses in mouse brain synaptosomes that require the nAchR a4 and b2 subunits (Marks et al. 1999) . The two a4-and b2-dependent components can be separated into a DHbE-sensitive and a DHbE-resistant component. A comparison of the pharmacological profile of the mma4b2 cells with that of agonistinduced 86 
Rb
+ efflux from mouse brain synaptosomes indicates that the mma4b2 cells exhibit an agonist pharmacology most similar to the DHbE-sensitive component (Fig. 7) ; the regression line for this comparison is essentially superimposed upon the line of identity (r ¼ 0.875, slope ¼ 1.00). In contrast, the regression line for the comparison between the EC 50 values for the mma4b2 cells and the DHbE-resistant response is distinct from the line of identity (r ¼ 0.94, slope ¼ 0.71). Agonist efficacies are also most similar between the mma4b2 cells and the DHbE-sensitive response (Table 1) One potential explanation for the pharmacological differences between the mouse brain synaptosomes and mma4b2 cells is the fact that the synaptosomes were prepared from a mouse strain that expresses an a4 subunit that has a threonine at amino acid position 529, whereas the mma4b2 cell line expresses a receptor with an alanine at this position. Previous studies have shown that this polymorphism influences receptor function (Dobelis et al. 2002; Kim et al. 2003) . The development of a cell line that expresses an a4b2 nAchR with the threonine variant of the a4 subunit would be useful to address this issue.
One striking difference in the pharmacology of the mma4b2 cell line relative to the reported pharmacology of other a4b2 nAchRs is the very low IC 50 value of the mma4b2 cell line for MLA. The IC 50 value of 31 ± 1.2 nM for MLA inhibition of receptor function in the mma4b2 cells is not only lower than the IC 50 value observed for this antagonist in inhibiting the DHbE-sensitive component of 86 
+ efflux (Marks et al. 1999) , it also is considerably lower than the reported low micromolar IC 50 values for MLA inhibition of other heterologous a4b2 nAchR expression systems (Buisson et al. 1996; Eaton et al. 2003) . MLA has been shown to inhibit a7-containing nAchRs with IC 50 values in the high picomolar to low nanomolar range (Alkondon et al. 1992; Palma et al. 1996; Virginio et al. 2002; Zhou et al. 2003) . Owing to the substantial differences in reported IC50 values for MLA inhibition of a7 nAchRs versus other nAchR subtypes, MLA is generally regarded as a highly selective antagonist for nAchRs comprised of the a7 subunit. However, in addition to the data reported here, others have reported that MLA can inhibit non-a7-mediated responses in the low nanomolar range. Clarke and Reuben (1996) demonstrated that nicotine-stimulated [ 3 H]-dopamine release from rat brain striatal synaptosomes can be inhibited by MLA with an IC 50 value of 38 nM. Similarly, Grady et al. (1997) (Rapier et al. 1990; Grady et al. 1992) and nicotinic agonist-stimulated [ 3 H]-dopamine release does not differ between a7 subunit null mutant mice and their wild-type controls (Salminen et al. 2004) . In contrast, Grady et al. (2002) Mogg et al. (2002) have shown that a presumed a3/a6b2b2 nAchR in rat striatum is inhibited by low nanomolar concentrations of MLA. These data indicate that MLA can inhibit non-a7-mediated responses at low nanomolar concentrations in heterologous expression systems as well as in rodent brain synaptosomes and suggest that this antagonist may not be as selective in the low nanomolar range for a7-containing nAchRs as previously thought.
The inhibition of non-a7-mediated responses by low nanomolar concentrations of MLA was observed in neurotransmitter release and intracellular calcium-based assays. In contrast, the reported inhibition of a4b2 nAchRs by high nanomolar to low micromolar concentrations of MLA were determined by ion flux (Marks et al. 1999; Eaton et al. 2003) and electrophysiological (Buisson et al. 1996) assays. Therefore, the potency of MLA at inhibiting nAchR-mediated responses may be dependent upon the assay used to evaluate the drug. In support of this possibility, we have determined the IC 50 value for MLA inhibition of mma4b2 receptor function using whole-cell patch-clamp electrophysiology. Using this method, we observed an IC 50 value for MLA of 0.43 ± 1.2 lM (data not shown). This IC 50 value for MLA is more consistent with the IC 50 values previously reported for MLA inhibition of a4b2 nAchRs when measured by 86 Rb + efflux or electrophysiological methods (Buisson et al. 1996; Marks et al. 1999; Eaton et al. 2003) . Fitch et al. (2003) also found significant differences in the pharmacology of an a3b4 cell line when evaluated by different methods. This group observed that the nicotinic antagonist mecamylamine was equipotent at inhibiting receptor function in an intracellular calcium assay and an 86 Rb + efflux assay but~25-fold less potent at inhibiting responses in the membrane potential assay. The agonist A85380 also was~6-fold less potent at stimulating responses in the intracellular calcium assay compared with the 86 Rb + efflux assay and 30 times less potent when compared with the membrane potential assay. Other substantial differences in agonist pharmacologies across methodologies were also reported by Fitch et al. (2003) . Unfortunately, MLA was not evaluated in this study. Similarly, in the mma4b2 cells, considerable differences Function of mouse a4b2 nicotinic receptors 1147 in the potencies of Ach (EC 50 , aequorin: 66.3 ± 2.2 lM; whole-cell recording: 179 ± 22 lM), TMA (EC 50 , aequorin: 46.9 ± 0.36 lM; whole cell recording: 243 ± 1.1 lM; data not shown) and MLA (IC 50 , aequorin: 0.03 ± 0.0012 lM; whole-cell recording: 0.43 ± 1.2 lM) were observed when determined by aequorin and electrophysiological methods. Ach, TMA and MLA were the only compounds tested in the mma4b2 cells by both methods. Regardless, these data and the data reported by Fitch et al. suggest that caution should be used when assigning the nAchR subtype specificity of a nicotinic compound based on the potency of the compound as determined by a single method of functional analysis.
The data reported here also established that the a4b2 nAchR-mediated increase in intracellular calcium in the mma4b2 cells is due predominantly to direct entry of calcium through the receptor channel. Release of calcium from both ryanodine-and IP 3 -sensitive intracellular stores also appears to contribute to the increase in intracellular calcium. Dantroline, another inhibitor of ryanodine-sensitive calcium release, inhibited epibatidine-evoked changes in intracellular calcium to the same extent as ryanodine (data not shown) indicating that the effect of ryanodine on intracellular calcium release was not due to a non-specific effect of the drug. However, it cannot be entirely ruled out that the apparent blockade of IP 3 -sensitive calcium stores by xestospongin C is due to a non-specific effect of the drug such as blockade of the nAchR channel or other ion channel (Ozaki et al. 2002) . There was no detectable contribution of high-voltage-sensitive calcium channels to the rise in intracellular calcium. However, HEK293T cells likely do not possess the full complement of voltage-sensitive calcium channels present in neurons. Therefore, these results must be interpreted with caution. Regardless, these data suggest that a4b2 nAchRs do not require the contribution of highvoltage-sensitive calcium channels in order to elicit a discernable rise in intracellular calcium. The lack of requirement for voltage-sensitive calcium channels for a4b2-mediated changes in intracellular calcium is consistent with other reports on heterologously expressed a4b2 nAchRs (Chavez-Noriega et al. 2000; Michelmore et al. 2002) and a4b2 nAchRs measured in situ (Nayak et al. 2001) .
Previous studies have shown that the mechanism of nAchR-mediated changes in intracellular calcium levels is subtype specific (Gray et al. 1996; Tsuneki et al. 2000; Shoop et al. 2001; Dajas-Bailador et al. 2002) . For example, several groups have reported that a7 subunit-containing nAchRs do not require the contribution of voltage-sensitive calcium channels in order to elicit agonist-induced changes in intracellular calcium (Gray et al. 1996; Tsuneki et al. 2000; Shoop et al. 2001; Dajas-Bailador et al. 2002) . In contrast, changes in intracellular calcium resulting from the stimulation of some nAchRs that contain the a3 subunit (Shoop et al. 2001; Dajas-Bailador et al. 2002) and some nAchRs that contain the b2 subunit (Tsuneki et al. 2000) appear to require the activation of voltage-sensitive calcium channels. This suggests that the effect of nAchR activation on calcium-dependent cellular processes depends upon which particular subtype or subtypes are activated. Therefore, nicotinic agonist effects on such calcium-dependent cellular processes as signal transduction pathways, transcription factor expression and activation, synaptic plasticity and neuroprotection would depend upon which nAchR subtype is activated. Further studies to evaluate nAchR subtype-specific changes in intracellular calcium and the affected downstream signaling pathways should provide a better appreciation for the role of specific nAchR subtypes in brain function and disease.
